Inherited IRF9 deficiency: a novel genetic etiology of severe influenza

遗传性 IRF9 缺陷:严重流感的新遗传病因

基本信息

  • 批准号:
    9510816
  • 负责人:
  • 金额:
    $ 25.43万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-02-09 至 2020-01-31
  • 项目状态:
    已结题

项目摘要

Project Summary Influenza A virus (IAV) is a zoonotic pathogen that causes seasonal epidemics annually and has the potential to cause worldwide pandemics. Life-threatening pneumonia occurs in only a small minority of infected individuals (0.04-0.4% of cases). Pre-existing pulmonary disease and acquired immunodeficiencies are well- known risk factors. The vast majority of severe influenza cases, however, remain unexplained, especially in children. Intriguingly, classical primary immunodeficiencies do not predispose to severe influenza. We recently reported an otherwise healthy child with severe influenza due to inherited autosomal recessive (AR) IRF7 deficiency resulting in impaired interferon (IFN)-α/β production in both plasmacytoid dendritic cells (pDCs) and induced pluripotent stem cell (iPSC)-derived pulmonary epithelial cells (PECs). This was the first demonstration that influenza susceptibility could be heritable. We hypothesize that additional cases of severe influenza in children and young adults may result from single-gene inborn errors of immunity, not necessarily displaying complete penetrance. We recently performed whole-exome sequencing (WES) in a cohort of 25 patients and their parents (trio design) with life-threatening influenza without secondary bacterial pneumonia. We discovered a homozygous IRF9 mutation in a child with life-threatening influenza and a history of adverse reaction to MMR vaccination. IRF9, with STAT1 and STAT2, is one of the three subunits of ISGF3, the main transcriptional complex that drives antiviral type I IFN responses. The mutation is private to this kindred and affects an essential nucleotide at a splice site. We intend to test whether the mutation is deleterious, in terms of expression and function. We will also test the patient's cells for response to type I IFN and their control of influenza virus in the presence of type I IFNs. Finally, we will compare the genome-wide transcriptome responses to type I IFNs in the patient's cells with those from other patients with autosomal recessive, complete defects in IFNAR1, IFNAR2, STAT1, and STAT2. Our preliminary data are convincing and strong, as we showed that the splice mutation is not leaky and the encoded protein is loss of ISGF3 expression and function. Moreover, the patient's cells seem to control influenza virus poorly even in the presence of exogenous type I IFNs. Finally, we have collected cells from patients with all types of inborn errors of the type I IFN responsive pathway. Our project is thus highly innovative, yet supported by strong preliminary evidence. Collectively, our project will characterize, in depth, the molecular and cellular basis of a new primary immunodeficiency, autosomal recessive IRF9 deficiency, thereby documenting a second genetic and immunological etiology of severe influenza of childhood. This study will give weight to the emerging notion that severe influenza of childhood can be caused by single-gene inborn errors of immunity. Our study will also have new and important biological implications, providing the first analysis of IRF9-dependent and -independent responses to type I IFNs in humans. Overall, our discovery will have both biological and clinical implications.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jean-Laurent Casanova其他文献

Jean-Laurent Casanova的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jean-Laurent Casanova', 18)}}的其他基金

Human Genetics of Tuberculosis
结核病的人类遗传学
  • 批准号:
    10430226
  • 财政年份:
    2021
  • 资助金额:
    $ 25.43万
  • 项目类别:
Human Genetics of Tuberculosis
结核病的人类遗传学
  • 批准号:
    10268806
  • 财政年份:
    2021
  • 资助金额:
    $ 25.43万
  • 项目类别:
Inborn errors of immunity in patients with life-threatening COVID-19
危及生命的 COVID-19 患者先天性免疫缺陷
  • 批准号:
    10655372
  • 财政年份:
    2021
  • 资助金额:
    $ 25.43万
  • 项目类别:
Inborn errors of immunity in patients with life-threatening COVID-19
危及生命的 COVID-19 患者先天性免疫缺陷
  • 批准号:
    10278180
  • 财政年份:
    2021
  • 资助金额:
    $ 25.43万
  • 项目类别:
Inborn errors of immunity in patients with life-threatening COVID-19
危及生命的 COVID-19 患者先天性免疫缺陷
  • 批准号:
    10449276
  • 财政年份:
    2021
  • 资助金额:
    $ 25.43万
  • 项目类别:
Human Genetics of Tuberculosis
结核病的人类遗传学
  • 批准号:
    10621305
  • 财政年份:
    2021
  • 资助金额:
    $ 25.43万
  • 项目类别:
Molecular and cellular basis of epidermodysplasia verruciformis
疣状表皮发育不良的分子和细胞基础
  • 批准号:
    10561607
  • 财政年份:
    2020
  • 资助金额:
    $ 25.43万
  • 项目类别:
Monogenic basis of resistance to SARS-CoV2 and predisposition to severe COVID-19
抗 SARS-CoV2 的单基因基础和严重 COVID-19 的易感性
  • 批准号:
    10159675
  • 财政年份:
    2020
  • 资助金额:
    $ 25.43万
  • 项目类别:
Molecular and cellular basis of epidermodysplasia verruciformis
疣状表皮发育不良的分子和细胞基础
  • 批准号:
    10352425
  • 财政年份:
    2020
  • 资助金额:
    $ 25.43万
  • 项目类别:
Molecular and cellular basis of epidermodysplasia verruciformis
疣状表皮发育不良的分子和细胞基础
  • 批准号:
    9887337
  • 财政年份:
    2020
  • 资助金额:
    $ 25.43万
  • 项目类别:

相似海外基金

A personalised approach to manage adverse reactions to CFTR modulator therapy in patients with cystic fibrosis
治疗囊性纤维化患者 CFTR 调节剂治疗不良反应的个性化方法
  • 批准号:
    MR/X00094X/1
  • 财政年份:
    2022
  • 资助金额:
    $ 25.43万
  • 项目类别:
    Research Grant
Identifying genetic polymorphisms and elucidating polygenic architecture associated with adverse reactions due to rituximab
识别遗传多态性并阐明与利妥昔单抗不良反应相关的多基因结构
  • 批准号:
    22K15910
  • 财政年份:
    2022
  • 资助金额:
    $ 25.43万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanistic study of sulfa drug-induced severe cutaneous adverse reactions by focusing on HLA-A*11:01
以HLA-A*为重点的磺胺类药物致严重皮肤不良反应机制研究11:01
  • 批准号:
    22K06738
  • 财政年份:
    2022
  • 资助金额:
    $ 25.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Severe Cutaneous Adverse Reactions Following Outpatient Antibiotic Therapy: A Population-based Study
门诊抗生素治疗后的严重皮肤不良反应:一项基于人群的研究
  • 批准号:
    449379
  • 财政年份:
    2020
  • 资助金额:
    $ 25.43万
  • 项目类别:
    Studentship Programs
Significance of gamma-chain in severe cutaneous adverse reactions
伽马链在严重皮肤不良反应中的意义
  • 批准号:
    19K17779
  • 财政年份:
    2019
  • 资助金额:
    $ 25.43万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Historical sociology of adverse reactions related to vaccination in Japan
日本疫苗接种不良反应的历史社会学
  • 批准号:
    18K00267
  • 财政年份:
    2018
  • 资助金额:
    $ 25.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
SEARCH (active Surveillance and Evaluation of Adverse Reactions in Canadian Healthcare) & PREVENT (Pharmacogenomics of Adverse Reaction EVEnts National Team)
SEARCH(加拿大医疗保健不良反应的主动监测和评估)
  • 批准号:
    379425
  • 财政年份:
    2018
  • 资助金额:
    $ 25.43万
  • 项目类别:
    Operating Grants
IGF::OT::IGF SBIR Phase II: Topic 338 - Predictive Biomarkers of Adverse Reactions to Prostrate Cancer Radiotherapy
IGF::OT::IGF SBIR II 期:主题 338 - 前列腺癌放射治疗不良反应的预测生物标志物
  • 批准号:
    9576448
  • 财政年份:
    2017
  • 资助金额:
    $ 25.43万
  • 项目类别:
Development of in silico prediction method for idiosyncratic adverse reactions associated with HLA genotypes
与 HLA 基因型相关的特殊不良反应的计算机预测方法的开发
  • 批准号:
    16K15156
  • 财政年份:
    2016
  • 资助金额:
    $ 25.43万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Characterising the Immune Response to Drugs That Cause Idiosyncratic Adverse Reactions
表征对引起特殊不良反应的药物的免疫反应
  • 批准号:
    367156
  • 财政年份:
    2016
  • 资助金额:
    $ 25.43万
  • 项目类别:
    Studentship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了